Business Description
Cabio Biotech (Wuhan) Co Ltd
ISIN : CNE100005X31
Share Class Description:
SHSE:688089: Class ATotal Employee Number:
595Compare
Compare
Traded in other countries / regions
688089.China Index Membership
SSE Composite Index IPO Date
2019-12-19Description
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.87 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | 3.05 | |||||
Interest Coverage | 25.65 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 4.42 | |||||
Beneish M-Score | -3.93 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.6 | |||||
3-Year EBITDA Growth Rate | 29.5 | |||||
3-Year EPS without NRI Growth Rate | 59.9 | |||||
3-Year Book Growth Rate | 4.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.9 | |||||
9-Day RSI | 41.35 | |||||
14-Day RSI | 38.3 | |||||
3-1 Month Momentum % | -39.32 | |||||
6-1 Month Momentum % | -42.37 | |||||
12-1 Month Momentum % | -55.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.76 | |||||
Quick Ratio | 2.8 | |||||
Cash Ratio | 1.81 | |||||
Days Inventory | 269.1 | |||||
Days Sales Outstanding | 158.17 | |||||
Days Payable | 102.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.89 | |||||
Dividend Payout Ratio | 0.59 | |||||
3-Year Dividend Growth Rate | -5.2 | |||||
5-Year Yield-on-Cost % | 1.21 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -3.38 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 43.41 | |||||
Operating Margin % | 15.02 | |||||
Net Margin % | 13.19 | |||||
EBITDA Margin % | 16.24 | |||||
FCF Margin % | 23.23 | |||||
OCF Margin % | 53.67 | |||||
ROE % | 3.42 | |||||
ROA % | 3 | |||||
ROIC % | 3.29 | |||||
3-Year ROIIC % | 11.65 | |||||
ROC (Joel Greenblatt) % | 5.9 | |||||
ROCE % | 4.04 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 32.15 | |||||
Forward PE Ratio | 8.95 | |||||
PE Ratio without NRI | 31.11 | |||||
Shiller PE Ratio | 15.3 | |||||
PEG Ratio | 6.1 | |||||
PS Ratio | 4.25 | |||||
PB Ratio | 1.12 | |||||
Price-to-Tangible-Book | 1.16 | |||||
Price-to-Free-Cash-Flow | 18.23 | |||||
Price-to-Operating-Cash-Flow | 7.9 | |||||
EV-to-EBIT | 23.77 | |||||
EV-to-EBITDA | 23.77 | |||||
EV-to-Revenue | 3.86 | |||||
EV-to-FCF | 16.61 | |||||
Price-to-GF-Value | 0.51 | |||||
Price-to-Projected-FCF | 1.85 | |||||
Price-to-DCF (Earnings Based) | 2.69 | |||||
Price-to-DCF (FCF Based) | 1.58 | |||||
Price-to-Graham-Number | 1.26 | |||||
| Price-to-Net-Current-Asset-Value | 3.79 | |||||
| Price-to-Net-Cash | 32.15 | |||||
Earnings Yield (Greenblatt) % | 4.21 | |||||
FCF Yield % | 5.44 | |||||
Forward Rate of Return (Yacktman) % | -4.96 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cabio Biotech (Wuhan) Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 418.184 | ||
| EPS (TTM) (Â¥) | 0.33 | ||
| Beta | 1.4282 | ||
| 3-Year Sharpe Ratio | -0.37 | ||
| 3-Year Sortino Ratio | -0.51 | ||
| Volatility % | 34.03 | ||
| 14-Day RSI | 38.3 | ||
| 14-Day ATR (Â¥) | 0.550689 | ||
| 20-Day SMA (Â¥) | 10.9215 | ||
| 12-1 Month Momentum % | -55.16 | ||
| 52-Week Range (Â¥) | 10.22 - 31.13 | ||
| Shares Outstanding (Mil) | 168.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cabio Biotech (Wuhan) Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cabio Biotech (Wuhan) Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.200940 Cash Dividend | 2025-07-10 | 24.92 (+0.12%) | ||
| 1.4:1 Stock Split | 2023-07-18 | 20.73 (-1.76%) |
Show
Entries
Cabio Biotech (Wuhan) Co Ltd Frequently Asked Questions
What is Cabio Biotech (Wuhan) Co Ltd(SHSE:688089)'s stock price today?
The current price of SHSE:688089 is ¥10.61. The 52 week high of SHSE:688089 is ¥31.13 and 52 week low is ¥10.22.
When is next earnings date of Cabio Biotech (Wuhan) Co Ltd(SHSE:688089)?
The next earnings date of Cabio Biotech (Wuhan) Co Ltd(SHSE:688089) is .
Does Cabio Biotech (Wuhan) Co Ltd(SHSE:688089) pay dividends? If so, how much?
The Dividend Yield %  of Cabio Biotech (Wuhan) Co Ltd(SHSE:688089) is 1.89% (As of Today), Highest Dividend Payout Ratio of Cabio Biotech (Wuhan) Co Ltd(SHSE:688089) was 1.27. The lowest was 0.26. And the median was 0.6. The  Forward Dividend Yield % of Cabio Biotech (Wuhan) Co Ltd(SHSE:688089) is 0%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Cabio Biotech (Wuhan) Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers